Having trouble accessing articles? Reset your cache.

Shire to appeal proposed ProAmatine withdrawal

Shire plc (LSE:SHP; NASDAQ:SHPGY) said it no longer intends to withdraw ProAmatine midodrine and now plans to appeal FDA's proposal to pull the orthostatic

Read the full 243 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE